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Introduction
"Dual diagnosis" is a term that has been used in the psychiatric literature for
over a quarter of a century to refer to patients with a psychiatric disorder and a co-
occurring substance abuse disorder. It has been well documented that these patients
utilize significantly greater amounts ofhealth care resources than single diagnosis
patients and have relatively poor treatment outcomes. Through recognition ofthe
prevalence ofthese dual diagnosis patients, their demographics, and treatment
outcomes, behavioral health care delivery systems have been able to tailor treatment
programs to their unique needs.
Currently, however, there is little data in the health services literature on
patients with other dual diagnoses, such as two co-occurring psychiatric disorders.
It would be beneficial to know about other combinations ofdiagnoses, their
prevalence, demographics, and resource utilization patterns.
Also, by using a reliable outcomes assessment tool, it would be helpful to
determine which dual diagnosis pairs (including but not limited to psychiatric plus
substance abuse) have significantly different outcomes when compared to patients
with only a single diagnosis. It is possible that the addition ofa second diagnosis
results in no change in some instances while in others it significantly affects
outcome. By investigating this, new dual diagnosis pairs might be identified with
specific needs that could be targeted by treatment facilities much like patients with
substance abuse and co-occurring psychiatric disorders have been in recent years.
Potential imeractions between various psychopathologies may also be elucidated.
The purpose ofthis investigation is a descriptive analysis ofpsychiatric
patients with single diagnoses and dual diagnoses including co-occurring psychiatric
disorders and psychiatric disorders with substance abuse disorders. The treatmem
outcomes and lengths of stay at treatment facilities will be described for these
patients. Through this analysis it may be possible to describe new pairs of dual
diagnoses that occur at significant rates and have significant effects on outcome and
length of stay. This may ultimately lead to more effective and targeted behavioral
imerventions for these patients.
Background
The co-occurrence ofdrug abuse with psychiatric disorders has been noted
in the scientific literature since at least the 1960s. Cohn and Klein, in one early
study in December of 1966, used a chart review ofpatients admitted to a psychiatric
hospital to show that 31 percent ofpatients had a history ofdrug abuse,z Many
other authors at the time reported similar findings.3’’’ In the late 1980s, the
problem magnified as state psychiatric institutions began to downsize and many
patients who would have previously been hospitalized were now living in the
community.7 This gave patients much greater access to drugs ofabuse and
clinicians were faced with increasing numbers ofpsychiatric patiems who were
substance abusers,s Also in the 1980s, the Epidemiologic Catchment Area program
completed a large population-based, multi-center study to determine incidence and
prevalence ofpsychiatric disorders.9 Analysis ofthese data showed that substance
abuse and psychiatric disorders were co-occurring at rates higher than would be
predicted by chance alone. The study found the prevalence of substance abuse in
the general population was 17 percent, while it was 48 percent among
schizophrenics, 56 percent among bipolar patients, and 24 percent among anxiety
disorder patients.
Many other studies since that time have defined the demographics of
psychiatric patients who are also substance abusers. These patients are most likely
to be male, young, single, and less educate1.12’13 It has also been shown that for
mentally ill persons, homelessness, incarceration, and presentation to an emergency
room are associated with increased risk ofa co-existing substance abuse disorder.4
Other studies have shown that patients with substance abuse and a psychiatric
disorder are at significantly higher risk for many adverse events including
homelessness, ]’]6 violence,]zs incarceration, J9 significantly higher than average
use ofmental health services,2’1 treatment non-compliance,’a and even I-ISIV
infection.
In the 1980s, the literature began to denote these patients as having a "dual
diagnosis." Studies also revealed that these patients had relatively poor treatment
outcomes compared to single diagnosis patients. A study in 1983 by Mclellan
showed that presence ofa psychiatric disorder was a major predictor ofpoor
outcome from a substance abuse program.2 Using a symptom list that included
presence or absence of symptoms, frequency, and duration, the authors compared
outcomes ofpatients-with only a substance abuse disorder (alcohol or other drugs)
to those with various severities ofconcomitant psychiatric disorders. Analysis
revealed that patients with low psychiatric severity had good outcomes regardless of
which type oftreatment program they entered. Patients with high psychiatric
severity had poor outcomes regardless ofwhich type oftreatment they underwent.
And patients with mid-level psychiatric severity showed wide ranging outcomes
depending on which treatment program they entered. This helped to clarify what
had previously been a troubling question about why benefit from substance abuse
treatments varied so widely among patients.
Early reviews ofthe services that dual diagnosis patients received revealed
two major problems.6 First, these patients typically received no substance abuse
treatment apparently due to difficulty in accessing services. Second, when they did
receive substance abuse treatment it was not tailored to the special needs ofdual
diagnosis patients. Much ofthese difficulties were attributed to a historical split
between mental health services and substance abuse services. For years this has
been the case, with separate providers, financing arrangements, and treatment
facilities for the two areas. As a result patients oten got care for only one oftheir
problems or separate, fragmented treatments for both.
Recognition ofthese problems in the late 80s and early 90s led to calls for
integrated treatment programs for these patients.25 New programs rapidly evolved
and many have been assessed through prospective studies. Drake et al.27 published
a comprehensive review ofthe literature on integrated treatment programs in 1998,
reporting on 36 completed studies in the literature.
Through recognition ofthe specific problems encountered by patients with a
psychiatric disorder and a substance abuse disorder, newer and more effective
treatments have been designed. In the study presented here, dual diagnosis patients
will similarly be analyzed, through description of demographics, outcomes, and
lengths of stay. In addition, this study will examine patients with other
combinations oftwo diagnoses such as two co-existing psychiatric disorders.
Through doing this, further knowledge can be gained regarding patients with
multiple psychiatric disorders and their needs.
Methods
Study Design
This study is a retrospective descriptive analysis ofprimary diagnoses and
dual diagnosis pairs. The question to be addressed is whether are there significant
differences in treatment outcomes and lengths of stay in patients with dual
diagnoses compared to those with a single diagnosis. Specifically, the analysis will
examine which combinations ofdual diagnoses have significant e,ffe,cts on outcome
and length of stay.
Data Source
Data for this project, were collected via the PsychSentinel.outcome
measurement program, which has been run by Dr. Hal Mark ofthe University of
Connecticut Department ofCommunity Medicine for the past 7 years.2s Through
this program 11 psychiatric treatment centers in the Connecticut area and 45 in the
U.S. assess the clinical outcomes oftheir behavioral health care treatmems. These
inpatient and outpatient psychiatric units complete data collection forms on each
patient at admission to their program and again at discharge. Using the information
on the forms,, t.he.patients are classified into clinically distinct popu!otions based on
diagnosis, level ofcare, and age. Then an outcome measure is determined, risk
adjusted, and compared to reference norms (see below). As the psychiatric
programs submit more forms, aggregate information is compiled for each program
regarding the. patient population, outcomes, and lengths of stay. The analyzed data
are reported to the treatment programs when 150 cases or more are available for
analysis. For some programs the data are used to maintain their JCAHO
accreditation.
For the purpose ofthis study, PsychSentinel data collection and analysis
methods will be generally described. Complete details on PyschSeminel including
information on reliability and validity ofdata have been published elsewhere.9
Data collection on each patient begins with treatment programs completing a data
collection form at admission (see appendix 1). Three major categories of
information are collected about the patients: descriptive and demographic data,
clinical difficulty data, and symptom data. The descriptive and demographic data
variables are listed in Table 1. Table 2 lists items collected as clinical difficulty
data. In general, the descriptive and demographic data is used to define the patient’s
background and clinical difficulty data is used to risk adjust the outcomes, as will be
discussed below. Occasional overlap, however, occurs since items such as age may
be used as descriptive data and also to determine clinical difficulty.
Table I Descriptive and Demographic Variables
Program Type
Re,admission status
Critical Pathway Used3
Age
Gender
Race
Marital Status
Pay Source
Program Type refers to classifying patients as inpatient or ouent.
Readmission status refers to classifying patients as either readmissions or new admissions
to a particular institution.
The critical pathway item is a yes or no answer regarding whether the treatment program
used a critical pathway.
Table 2- Clinical Difficulty Items
Reason for Entering Treatment
History of Substance Abuse2
Suicide Potential
History ofAssault2
Concurrent Physical Illness2
Employment Status
Residential Status3
Inpt. Psychiatric or Substance Abuse Admission in past 12 Months
History of Inpatient Psychiatric or Substance Abuse Admissions
Refers to classifying patients as "told to enter by a professional" or "self motivated".
These clinical diculty items are answered either"yes" or "no".
3 Refers to classifying patients as living alone, not living alone, or without a stable
residence.
The third type of information collected on each patient is symptom data.
Psychiatric treatment programs using PsychSentinel complete a symptom checklist
that notes the presence or absence ofsymptoms specific to the patient’s diagnosis.
There are 17 different symptom checklists, each corresponding to a particular
patient category (most ofthe categories correspond to the patient’s diagnosis with
the exception of substance abuse, which is split into two categories based on the
programmatic treatment goals for that patient). The checklists contain symptoms
taken from Diagnostic and Statistical Manual, 4th edition, a publication ofthe
American Psychiatric Association.3 For a patient with a particular diagnosis, each
symptom is checked as either "present" or "not present." Based on the patient’s
symptoms at initiation oftreatmem, a raw symptom intensity score, T1,w, is
calculated using numerical values assigned to each symptom that is present. Some
symptoms are more severe, and therefore carry a higher numerical value when
present. Thus Tl,w is a function ofthe number of symptoms present and the
relative weight given to each symptom. For example, a depressed patient may have
significant suicide risk, which carries a score of4, and poor concentration, which
carries a score of2. Ifno other symptoms were present, these would be the only
components ofthe T1, score. This hypothetical patient’s symptom intensity score
would be 6. The numerical value assigned to each symptom was determined at the
creation ofPsychSentinel via consultation with psychiatric professionals,a
For each diagnosis, the maximum value for TI is different. For example,
a schizophrenic patient with every symptom on the checklist present could have a
T1,, score of24 while a depressed patient with every symptom present may have a
T1,, score of 32. This makes comparison ofsymptom intensity scores across
different diagnostic categories problematic. To rectify this, the TI,, scores are
multiplied by a conversion factor to generate a standardized symptom intensity
score, T1, which ranges from 0 to 100 for every diagnosis. Thus a schizophrenic
patient with all symptoms present will have a score of 100 and a depressed patient
with all symptoms present will also have a score of 100. In this way, patients with
different diagnoses may be compared to one another in terms oftheir T 1 score.
At discharge, the data collection form is completed for each patient.
Information is added on length of stay and a reassessment ofthe patient’s
symptoms. All symptoms that were present at admission are reassessed as "not
improved", "improved", or "totally improved". The patient is given a standardized
symptom intensity score at discharge, T2 (calculated using the same conversion
methodology as for T 1). Using the initial and discharge standardized symptom
intensity scores, a change in symptom intensity, AT, can be calculated by
subtracting T2 from T1 as shown in equation 1.
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AT- T1-T2 (1)
AT is divided by TI to generate an outcome measure, the percent attainable
improvement, %A, as shown in equation 2.
%A T1- T2 (2)
T1
This value represents the percentage improvement in a patient’s symptom
intensity from admission to discharge, ranging from 0 to 100%, regardless of
diagnosis (100% being complete resolution ofadmission symptoms at discharge).
Thus for each patient treated an outcome measure, %A, and a length of stay (LOS)
value is determined.
RiskAdjustment ofData
To risk adjust the data, patients are first classified according to their
level of clinical difficulty by assigning them into either low or high clinical
difficulty categories. Their outcomes are then compared to those calculated from a
reference data set; a collection ofeases that provide norms (i.e., a benchmark). The
reference norms allow the determination ofa risk-adjusted average or "expected"
outcome that is compared to the observed values for patients in this study. For
example, a study patient may have a relatively low %A of 50. However, for patients
with the same diagnosis and clinical difficulty level in the reference database, the
average %A is 35. This %A of 50 is actually quite good when viewed in light ofthe
patient’s clinical difficulty level and associated reference norm.
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When PsychSentinel was originally launched, a baseline ofapproximately
36,000 reference cases was compiled (these cases were separate from those
analyzed for this study). Linear regression was performed using clinical difficulty
items relative to %A and LOS for all cases with a particular diagnosis. In doing
this, clinical difficulty items strongly predictive ofpoor outcomes, expressed as a
low %A or a long length of stay, were determined. For each single diagnosis (dual
diagnosis cases were not used in this analysis) items from Tables 1 and 2 that were
strong predictors of low %A and long LOS were identified. These characteristics
became the clinical difficulty items specific to each diagnosis. These items were
used to divide the reference cases into two groups: low clinical difficulty or high
clinical difficulty. The average or "expected" %A and LOS were determined for
each diagnosis for the low clinical difficulty and high clinical difficulty patiems
using the data from the reference cases.
The clinical difficulty items used for each diagnosis in PsychSentinel are
proprietary and will not be mentioned here but the following example will serve to
illustrate the use ofthe reference cases in risk adjusting the data. For example,
suppose it had been determined that for patients with a diagnosis ofdepression in
the reference case set, the best predictors of a low %A were age5 and a positive
history ofassault. Patients with both ofthese elements in their history would be
considered high clinical difficulty cases. Cases with anything other than both of
these elements would be classified as low clinical difficulty. For this example,
assume those with a high clinical difficulty had an average %A of 50 and those with
a low clinical difficulty had an average %A of 70. These values of 50 and 70 would
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be used as "expected" %A for cases of similar clinical difficulty in the study data
set. By doing this data are risk adjusted since cases ofhigh clinical difficulty are
compared to the reference average of 50 whereas those of low clinical difficulty are
compared to the %A of 70.
The study data were split into cases oflow or high clinical difficulty using
the same diagnosis-specific clinical difficulty items as for the reference norms. For
dual diagnosis cases, the primary diagnosis ofthe pair was used to select the
appropriate reference norm for use as expected %A and LOS. The clinical difficulty
ofthe study patients had to be known so the correct "expected" %A and LOS from
the reference norms could be used. The actual %A and LOS for the study cases was
compared to the "expected" %A and LOS from the reference norm data set. A ratio
ofobserved to expected %A, O/E %A, was calculated using equation 3.
%Aobserved
O / E%A (3)%Aexp coted
In this equation the observed %A came from our data set and the expected
%A came from the reference cases that were ofthe same clinical difficulty. The
same was done for length of stay using equation 4.
LOSobsrvedO/ELOS (4)
LOSexpected
For %A the ratio of observed divided by expected is used so that higher
values for this ratio represent better than expected outcomes. For LOS the ratio of
observed divided expected is also used; however, lower values for LOS,,d
represent a better length of stay. This means that the O/E LOS value is less than one
when observed LOS is better than expected. When considering O/E %A and O/E
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LOS values, it must be kept in mind that O/E %A values greater than 1 indicated
better than expected outcomes and O/E LOS values less than one indicated better
than expected length of stay. These opposite ratios ofobserved to expected occur
for %A and LOS because a higher %A represents a better outcome for the %A
variable while a lower LOS represents better result for the LOS variable. Use of
equations 3 and 4 to calculate observed to expected ratios provides risk adjusted
measures for %A and LOS. %A values which may be low (poor outcome) may
have a high O/E %A ifthe %A achieved was actually higher relative to the risk-
adjusted expected %A.
Patient Diagnoses
Part ofthe data collection form completed on each patient includes the
patient’s diagnosis. The various diagnoses assigned to patients in the study are
listed in Table 3. The PsychSentinel data collection form allows for listing ofeither
1 or 2 psychiatric disorders for a patient. Ifa patient has two diagnoses (so called
"dual diagnosis" patients), one disorder is listed as primary and one as secondary.
The primary diagnosis should be the disorder responsible for the majority ofthe
patient’s symptoms at the time ofadmission.
The patients’ diagnoses correspond to their descriptions in DSM-IV with
exception of patients being, treated for substance abuse. These patients were split
imo two groups: brief substance abuse and extended substance abuse. Brief
substance abuse patients were those admitted for stabilization and detoxification.
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Extended substance abuse patients were those treated in a long-term rehabilitation
program.
Table 3. Diagnoses of Patients in Study
Depression
Bipolar Disorder
Post Traumatic Stress Disorder
Dysthymia
Brief Substance Abuse
Extended Substance Abuse
Borderline Personality Disorder
Inclusion Criteria
A total of 19,414 cases collected as part ofthe PsychSentinel program from
1995 to 1999 were used for this study. Ofthese, 16,561 carried a single diagnosis
and 2,853 carried a dual diagnosis. In order to achieve greater consistency in the
data set, only patients from inpatient treatment facilities who were over 17 years of
age were used.
Initial analysis ofthe data set revealed that several dual diagnosis "pairs"
occurred infrequently. Since a minimum of 50 cases was deemed necessary for
analysis, pairs with less than this number of cases were eliminated from the data set.
For example, ifthe dual diagnosis ofbipolar disorder with posttraumatic stress
disorder (PTSD) occurred only 40 times in the data set, these 40 cases were
eliminated. This refining ofthe data set left 10 dual diagnosis pairs and a total of
1527 dual diagnosis cases for the study.
Since the purpose ofour study was to compare single to dual diagnosis cases
(i.e., look at outcomes when a diagnosis is single verses when it is within a pair), all
disorders present in the single diagnosis data set but not in the dual diagnosis data
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set were eliminated. Thus, for example, ifthere were 1O0 cases of briefpsychotic
disorder in the single diagnosis data set but brief psychotic disorder did not occur in
any ofthe dual diagnosis pairs, then these 100 cases were eliminated. This let 7
single diagnoses and a total of 11,296 cases in the single diagnosis data set. Table 4
lists the single and dual diagnoses along with their frequencies that make up the
final data set.
Table 4. Diagnoses and Frequencies of Study Patients
Single Diagnoses
Depression
Bipolar Disorder
Brief Substance Abuse
Extended Substance Abuse
PTSD
Borderline
Dysthymia
No.
Cases
7399
1688
1539
306
162
148
54
Dual Diagnoses
(primary/secondary)
Depression/Brief Substance Abuse
Depression/Borderline
Depression/Extended Substance Abuse
DepressionTSD
Brief Substance Abuse/Depression
BipolarfBrief Substance Abuse
Bipolar/Depression
Depression/Bipolar
Extended Substance Abuse/Depression
Borderline/Depression
Cases
480
277
174
129
117
108
75
64
52
51
StatisticalAnalysis
Statistical analysis was performed using SPSS for Windows version 10.1.
Means were compared with a one-way ANOVA or two-tailed t test for parametric
data. Where indicated the Kruskal-Wallis test non-parametric one-way ANOVA
was performed.
Results
Table 5 shows the outcomes and lengths of stay for all single and dual
diagnoses in the study. The %A and LOS columns represent the non risk-adjusted
outcomes and lengths of stay. The columns O/E %A and O/E LOS relesent the
observed to expected ratios of%A and LOS (i.e. risk adjusted %A and LOS
outcome measures).
Table 5. Average Outcomes and Lengths of Stay
%A LO_...S OIE LOS
Depression 63.9 8.0 1.0090 0.8521
Bipolar 62.1 I0.0 0.9886 1.0357
Brief SA 77.4 3.8 1.0573 0.8003
Extended SA 56.4 11.5- 0.7830 2.3359
PTSD 54.5 7.1 0.9076 1.06
Borderline 57.7 6.6 0.9757 0.6884
Dysthymia 57.5 8.0 0:9084 O.7223
Depression/Brief SA
Depression/Borderline
Depression/Extended SA
Depmssion/PTSD
Brief SA/Depression
Bipolar/Brief SA
Bipolar/Depression
Depression/Bipolar-
Extended SA/Depression
Borderline/Depression
71.1 6.3 1.1243 0.6875
56.8 8.1 0.9062 0.8247
60.8 8.7 0.9661 0.9133
62.2 8.9 0.9882 0.9739
68.0 4.9 0.9354 0.9961
69.0 8:1 1-.1016 08642
56.9 10.1 0:9037 1.0836
58.4 9.5 0.9286 0.9459
63.4 7.3 0.8948 1.4035
68.6 6.9 1.1678 0.8604
Table 6 lists results ofthe statistical comparison ofthe dual diagnosis pairs
to the stand-alone diagnoses. For each dual diagnosis pair in Table 6, the p value
listed is the result ofa comparison ofthe pair’s mean O/E %A or mean O/E LOS, to
that ofthe primary diagnosis as a stand-alone. For example, the p value of 0.550 for
depression/borderline O/E LOS in Table 6 indicates the significance ofa
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comparison ofthe mean O/E LOS for the pair (0.6875 in Table 5) to mean O/E LOS
for depression as a stand-alone diagnosis (0.8521 in Table 5).
Table 6. P values for Dual Diagnosis Pairs
Relative to Primary Diagnosis as Stand-Alone
Depression/Brief SA
Depression/Borderline
Depression/Extended SA
Depression/PTSD
Depression/Mania
Mania/Brief SA
Mani/Depression
Breif SA/Depression
Extended SA/Depression
Borderline/Depression
..OIE %A O/E LOS
P values P val,ues
<0.001" <0.001"
<0.001" 0.550
0.13(} 0.291
0.533 0.067
0.088 0.318
0.004* 0.026*
0.071 0.599
<0.001" 0.012"
0.009* <0.001"
0.005* 0.156
* Denotes significant (p<O.O5) difference between pair and primary diagnosis as stand-alone
Depression was the most common single diagnosis in the study. It also
occurred with significant frequency as a primary and secondary diagnosis in a pair.
Table 5 shows the changes in average O/E %A and O/E LOS when depression was
a stand-alone diagnosis and when it was part ofa dual diagnosis pair. Figure 1
shows the variation in average O/E %A when depression was a single diagnosis and
when it was the primary diagnosis in a dual diagnosis pair. Significant variation
(p<0.05) in depression as a stand-alone diagnosis compared to depression as
primary in a pair occurred only in the depressionrief substance abuse and
depression/borderline pairs. Figure 2 shows the variation in average O/E LOS when
depression was a stand-alone diagnosis and when it was primary in a dual diagnosis
pair. Only the depression/brief substance abuse pair had a significant change in
average O/E LOS compared to depression as a stand-alone diagnosis.
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Figure 1. Average O/E %A for Depression as a
Stand Alone and Primary in a Dual Diagnosis Pair
* Denotes significant (p<0.05) difference between pair and primary diagnosis as stand-alone
ii:.!i!i:..-.:..-:.:..::.!
:::::::::.’;:::::::::
::::::::::::::::::::::
::::::::.-.’::::::::
::’-:::::::2:::::.’:::
,:..:;:..:::-’...’..:-:.:..::::
!::::’.::;’.:.’:::::’.:::
::::::::::::::::::::::
::.’:::::::::::::::::::
::::::..::::::::::::::::
:::::::::::::::::::::
:::::.’::::::::::::..::
:::::;::::::::::::::-
:::::::::::::::::::::
Figure 2. Average O/E LOS for Depression as a Stand Alone and
Primary in a Dual Diagnosis Pair
Denotes significant (p<0.05) difference between pair & primary diagnosis as stand-alone
Bipolar disorder occurred second in frequency only to depression as a stand-
alone diagnosis. Figures 3 and 4 show the variation in average risk-adjusted %A
and LOS when bipolar was a stand-alone and when it was a primary diagnosis in a
dual diagnosis pair. The two dual diagnosis pairs that contained bipolar as a
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primary were bipolar/brief substance abuse and bipolar/depression. The former
showed a significantly different average OrE %A and O/E LOS compared to bipolar
alone while the latter did not change significantly for these variables.
Figure 3. Average O/E %A for Bipolar as a
Stand Alone and Primary in a Dual Diagnosis Pair
Denotes significant (p<0.05) difference between pair & primary diagnosis as stand-alone
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Figure 4. Average O/E LOS for Bipolar as a Stand Alone and
Primary in a Dual Diagnosis Pair
Denotes significant (p<0.05) difference between pair & primary diagnosis as stand-alone
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Brief substance abuse ranked 3a in frequency as a stand-alone diagnosis. Its
variation in average O/E %A and O/E LOS is shown in Figures 5 and 6. The only
dual diagnosis pair in which this diagnosis was primary was brief substance
abuse/depression. The addition ofdepression as a secondary diagnosis resulted in a
significantly different average risk-adjusted %A and risk adjusted LOS.
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Figure 5. Average O/ %A for Brief Substance Abuse as a Stand-Alone and
Primary in a Dual Diagnosis Pair
* Denotes significant (p<0.05) difference between pair and primary diagnosis as stand-alone
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Figure 6. Average O/E LOS for Brief Substance Abuse as a
Stand-Alone and Primary in a Dual Diagnosis Pair
Denotes significant (p<0.05) difference between pair and primary diagnosis as stand-alone
The variation in extended substance abuse average outcomes and lengths of
stay as a stand-alone and as primary in a dual diagnosis pair is illustrated in Tables 7
and 8. The only pair that contained extended substance abuse was extended
substance abuse/depression. This pair resulted in a significantly different average
O/E %A and O/E LOS compared to extended substance abuse alone.
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Figure 7. O/E %A for Extended Substance Abuse as a Stand-Alone and
Primary in a Dual Diagnosis Pair
* Denotes significant (p<0.05) difference between pair & primary diagnosis as stand-alone
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Figure 8. O/E LOS for Extended Substance Abuse as a Stand-Alone and
Primary in a Dual Diagnosis Pair
Denotes significant (p<0.05) difference between pair and primary diagnosis as stand-alone
The variation in average outcomes and lengths of stay for borderline as a
single diagnosis and primary in a dual diagnosis pair is shown in Tables 9 and 10.
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The only dual diagnosis with borderline as a primary was borderline/depression. In
this pair, the average O/E %A and O/E LOS changed significantly.
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Figure 9. O/E %A for Borderline as a Stand-Alone and
Primary in a Dual Diagnosis Pair
* Denotes significant (p<0.05) difference een pair & primary diagnosis as stand-alone
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Figure 10. O/E LOS for Bodedine as a Stand-Alone and Primary in a
Dual Diagnosis Pair
* Denotes signet (p<0.05) difference between pair and primary diagnosis as stand-alone
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PTSD and Dysthymia never occurred in a dual diagnosis pair as a primary.
They did, however, occur in several pairs as a secondary diagnosis. For thi reason
they were considered in the study and their outcomes and length of-ty data.as
single diagnoses are included in Table 5.
Discussion
Frequencies
Depression was the most common single diagnosis among the study patients.
This is not surprising considering the high prevalence ofdepression in American
society recently estimated at 21 to 24% ofthe population in women and 12 to 15%
in men.3 Brief substance abuse occurred 3 as a single diagnosis and extended
substance abuse occurred 4t. The combination ofthese two, however, represents
substance abuse ofany type and was the 2d most common single diagnosis with
1,845 cases (determined by adding together the frequencies ofbrief and extended
substance abuse in Table 4). This is also an expected finding in light ofthe high
prevalence of substance abuse in American society (it is estimated that 7 to 10
percent of adults are alcohol abusers33). Considering the significant frequencies of
depression and substance abuse as single diagnoses, it is not surprising that
combinations ofsubstance abuse and depression were common dual diagnosis pairs.
Adding together all the pairs in Table 4 that combine depression and substance
abuse (depression/brief substance abuse, depression/extended substance abuse, brief
substance abuse/depression, and extended substance abuse/depression) gives a total
of 823 cases or 53% of all the dual diagnosis cases in this study. Adding
bipolar/brief substance abuse to these 823 cases gives a total of931 cases that
represent all the dual diagnosis pairs that include substance abuse plus any
psychiatric disorder. This is the traditional definition of"dual diagnosis" patients in
the literature and represents 61 percem ofthe dual diagnosis cases in this study.
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This finding is consistent with literature regarding the high prevalence oftraditional
dual diagnosis patients.
One interesting item in Table 4 is that certain single diagnoses and dual
diagnosis pairs did not occur at significant frequencies. Brief substance abuse
occurred in a pair with depression and bipolar. It did not, however, appear at
significant rates with other psychiatric disorders such as schizophrenia. Many other
psychiatric disorders, such as the anxiety disorders and personality disorders,
occurred at low frequencies as stand-alone diagnoses and thus it is not surprising
that they were not present in many dual diagnosis pairs. Schizophrenia, however, is
relatively common (lifetime prevalence of 1.4%1]) and did have a significant rate as
a single diagnosis (1,454 cases), but was not included in the final data set because it
was not present at significant rates in any dual diagnosis pairs. With this relatively
high number ofpatiems with schizophrenia alone, it is surprising that no dual
diagnosis pairs occurred which included this diagnosis. Furthermore, the data from
the Epidemiological Catchmem Area Study show 48% of schizophrenics have co-
occurring substance abuse. It must be considered that a difficulty may exist in
recognizing or in coding patients with schizophrenia and co-occurring substance
abuse. Additionally, schizophrenia is a thought disorder while bipolar disorder and
depression are mood disorders. Perhaps some feature ofthought disorders makes
recognition or coding of co-existing substance abuse,more difficult.
Also notable from Table 4 is the lower frequency ofextended substance
abuse compared to brief substance abuse. As a single diagnosis, brief substance
abuse occurred 1539 times while extended substance abuse occurred only 306 times.
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This indicates that patients were far more likely to be treated for brief substance
abuse (i. e. stabilization) than for long-term therapy. This pattern was also present in
the dual diagnosis pairs. For depressed patients with a secondary diagnosis of
substance abuse, they were more often treated for brief substance abuse than for
extended substance abuse (480 verses 174 cases). In the case ofbipolar, the dual
diagnosis pair of bipolar/brief substance abuse occurred 108 times while
bipolar/extended substance abuse did not occur with enough frequency to be
included in the study (<50 cases).
Outcomes
The method for risk adjusting outcomes must be considered when comparing
single to dual diagnoses. For single diagnoses, clinical difficulty items were
available specific to each diagnosis and were used to risk adjust the data. For dual
diagnosis pairs, clinical difficulty items for the primary diagnosis were used to risk
adjust data for each pair. It is possible that if clinical difficulty items for each dual
diagnosis pair were known, the risk-adjusted outcomes would be different.
Development ofnew clinical difficulty items for dual diagnosis pairs would require
collection ofa new database ofreference cases and was not done as part ofthis
study.
Psychiatric Disorders andBriefSubstance Abuse
Depression showed significantly improved mean O/E %A and mean O/E
LOS when paired with a secondary diagnosis ofbrief substance abuse in a dual
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diagnosis pair (Figures 1 and 2). This finding is ofinterest since one might expect
the addition ofa secondary diagnosis ofbrief substance abuse to worsen outcomes
and increase lengths of stay relative to depression alone. Improved outcomes and
lengths of stay also occurred when bipolar disorder was paired with brief substance
abuse as a secondary diagnosis (Figures 3 and 4). This indicates that patients with a
primary psychiatric disorder ofdepression or bipolar and a secondary diagnosis of
brief substance abuse do better than patients that cma3t only a single diagnosis ofthe
corresponding psychiatric disorder. The explanation for this finding may lie in the
significant experience that treatment centers have in dealing with dual diagnosis
patients such as these. As mentioned in the introduction, there is ample literature on
treatmems for patients with substance abuse plus a psychiatric disorder. Since
depression and bipolar disorder are common psychiatric disorders, it is likely that
treatment centers have developed experience and strategies for these dual diagnosis
patients. Targeted treatment programs may be so effective that the dual diagnosis
patients respond better than single diagnosis psychiatric patients.
The situation is confused, however, with the finding that patients with a
primary diagnosis ofbrief substance abuse and a secondary diagnosis of depression
(Figures 5 and 6) did worse compared to brief substance abuse alone in terms of
mean O/E %A and O/E ILOS. This indicates that while treatment centers were
more effective at treating dual diagnosis patients when substance abuse was
secondary, the same was not true when substance abuse was primary. Furthermore,
a direct comparison ofcases with depression/brief substance abuse to brief
substance abuse/depression showed that depression/brief substance abuse had better
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outcomes and lengths of stay. This implies that patients with diagnoses of
depression and brief substance abuse responded differently in terms of outcomes
and lengths of stay depending on which diagnoses was primary (i.e., responsible for
most ofthe symptoms at admission). There may be an interaction between these
two diagnoses such that when substance abuse is primary, the patient’s depression
adds to the clinical difficulty oftreatment. Another possibility is that targeted
programs for these dual diagnosis patients are successful when depressive
symptoms dominate but less effective when substance abuse symptoms dominate.
Depression andExtendedSubstance Abuse
When depression was paired with extended substance abuse, there were no
significant changes in either mean O/E %A or mean O/1/LOS. This is surprising
since one might expect that the additional diagnosis ofextended substance abuse
would result in poorer outcomes and longer lengths of stay. As with brief substance
abuse treatment, this finding may be due to the extensive literature on recognition
and treatment ofpatiems with a psychiatric disorder plus substance abuse.
Experience with these patiems may allow treatment centers to achieve similar
outcomes and lengths ofstay compared to patients with only depression.
Looking at the reverse situation ofextended substance abuse as a primary
and depression as a secondary diagnosis is complicated (Figures 7 and 8). The
extended substance abuse/depression pair had worse mean O/E %A values but
improved mean O/E LOS values. A partial explanation for the improved mean O/E
LOS may lie in the exceptionally high mean O/E LOS for extended substance abuse
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alone of 2.33. This valu may b inflated due to a need for better referenc norms
since it seems unlikely that our study cases performed 2.33 times bettr than the
reference norms.
BriefSubstance Abuse andExtended Substance Abuse
In the stand-alone diagnoses (Table 5), brief substance abuse showed
significantly improved risk-adjusted outcomes and lengths of stay compared to
extended substance abuse (p values <0.001 for O/E%A and <0.001 for O/E LOS).
A similar trend was present in the dual diagnosis data where depression/brief
substance abuse showed improved risk adjusted outcomes and lengths of stay
relative to depression/extended substance abuse (p values <0.001 for O/E%A and
0.001 for O/E LOS). Also in th dual diagnosis cases, brief substance
abuseYdepression had better outcomes and lengths of stay compared to vxtended
substance abuse/depression. This indicates that treatment centers were more
successful in treating patients with brief substance abuse issues than those with
extended substance abuse issues regardless ofwhether the patient carried one
diagnosis or two. A possible explanation is that brief substance abuse needs (i.e.
stabilization) may be easier to meet than long term substance abuse needs.
Additionally there may be substance abusers that frequently present for brief
treatment and are successfully treated, but have a more difficult time meeting long-
term treatment goals.
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Depression andBipolar Disorder
When depression was paired with bipolar as a secondary diagnosis there
were no significant changes in mean risk adjusted outcome or length of stay
(Figures I and 2). The same occurred in the reverse pair ofbipolar as primary and
depression as a secondary diagnosis where mean risk adjusted outcomes were not
significantly different compared to bipolar alone (Figures 3 and 4). By definition,
patiems with bipolar disorder suffer from symptoms of mania and depression,
usually oscillating between a manic phase, where mania symptoms occur, and a
depressive phase, where depressive symptoms occur. It is therefore unclear why
some patients are coded as only having bipolar disorder (which by definition
includes depression) while others are coded as having bipolar disorder and
depression. It is unlikely that patients would have symptoms ofboth mania and
depression at the same time since bipolar patiems usually oscillate between
symptoms ofone or the other but not both. However, it does stand to reason that
patients with bipolar disorder who are coded with a primary diagnosis ofdepression
(i.e., depressive symptoms comprise the majority ofthere symptoms at admission)
should have similar outcomes and lengths of stay compared to depression alone
since both depressed patients and bipolar patients in a depressive phase suffer from
the same symptoms. By the same logic, it is also understandable that patients with a
primary diagnosis ofbipolar and a secondary diagnosis ofdepression have similar
outcomes and lengths of stay compared to bipolar disorder alone. Most likely these
patients coded as having depression and bipolar are actually no different from the
patients coded as having only bipolar.
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Depression andBorderline
When depression was paired with borderline (Figures 1 and 2), risk adjusted
outcomes were significantly worse compared to depression alone. Risk adjusted
lengths of stay, however, was not significantly altered compared to depression
alone. This implies that these dual diagnosis patients were treated for relatively the
same amount oftime as patients with only depression but had worse outcomes. The
reverse situation of borderline as a primary and depression as a secondary diagnosis
(Figures 9 and 10) showed that these patients had worse outcomes and lengths of
stay compared to borderline alone. Therefore, it appears that patients with
borderline personality disorder and depression have the same or worse length ofstay
compared to the stand-alone diagnoses and have consistently worse outcomes. The
explanation for this is unclear but may lie in the extreme difficulty ofresolving
depressive symptoms in patients with borderline personality disorder.
Depression andPTSD
Depression paired with PTSD showed no significant changes in mean risk
adjusted outcomes or lengths of stay compared to depression alone. This implies
that although these patients suffer from the additional diagnosis ofPTSD, this does
not significantly alter the effectiveness and duration oftreatment.
Conclusions and Future Work
This study determined the frequencies, outcomes, and lengths of stay for
single diagnoses and dual diagnosis pairs. The diagnoses of brief substance abuse,
extended substance abuse, depression, bipolar disorder, borderline personality
disorder, PTSD, and dysthmia occurred at significant rates in dual,diagnosis pairs
and therefore were included in the analysis. For unclear reasons, schizophrenia did
not occur at significant rates in any dual diagnosis pairs and thus it was excluded
from the study.
This study found that brief substance abuse treatment occurs far more often
than extended substance abuse treatment both as a single diagnosis and in a pair.
Furthermore, the outcomes and lengths of stay were better for patients treated for
brief substance abuse than for extended substance abuse.
The logical expectation that a adding a secondary diagnosis to a single
diagnosis would result in worse outcomes or longer lengths of stay did not occur in
several cases. The addition ofbrief substance abuse to depression or bipolar
disorder resulted in better outcomes and shorter lengths of stay. When depression
was paired with bipolar disorder or PTSD, outcomes were no differem compared to
depression alone. Also, when depression was paired with borderline, although
outcomes worsened, lengths of stay did not significantly change. This implies that
there may be interactions between these diagnoses such that the pairs perform the
same or better than the single diagnosis. Alternatively, there may be a selection
process occurring when providers code these patients such that those coded with
dual diagnoses are able to achieve the same or better outcomes than those with
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stand-alone diagnoses. A discussion with providers at the sites included in the study
may further elucidate the reasoning behind these relationships.
Brief substance abuse, extended substance abuse, and depression have a
complex interrelationship. In general, brief substance abuse had better outcomes
and lengths of stay than extended substance abuse, whether it was a single diagnosis
or part of a pair with depression. The brief substance abuse/depression pair showed
improved outcomes and lengths of stay when depression was primary compared to
the reverse situation when brief substance abuse was primary. Since the number of
cases (stand-alones and pairs) with these three diagnoses is large, it would be
beneficial to develop reference norms for each dual diagnosis pair to be used for risk
adjustment. This would answer several interesting questions. First, which clinical
difficulty items would be good risk adjusters for the pairs and would they be the
same as for the stand-alone diagnoses? This alone may shed some light on features
that are predictive ofpoor outcomes and how they vary within the dual diagnosis
pairs. Second, do the same relationships between single and dual diagnosis pairs
exist when the new risk adjusters are used? Ifthe same relationships exist, it can be
more confidemly stated that certain pairs do better than the stand-alone diagnoses
and that further investigation into the reasons behind these phenomena should be
done.
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